Effects of oral posaconazole on the pharmacokinetics of sirolimus

Current Medical Research and Opinion

Volumn 25, Issue 3, 2009, Pages 701-707

  Moton, Allen ^a   Ma, Lei ^a   Krishna, Gopal ^a   Martinho, Monika ^a   Seiberling, Michael ^b   McLeod, James ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Swiss Pharma Contract Ltd   (Switzerland)

Author keywords

CYP3A4; Pharmacokinetics; Posaconazole; Sirolimus

Indexed keywords

CYTOCHROME P450 3A4; POSACONAZOLE; RAPAMYCIN;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BLOOD CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; ELECTROCARDIOGRAPHY; ENZYME INHIBITION; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; QT PROLONGATION; SIDE EFFECT; SINGLE DRUG DOSE; SORE THROAT; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; VITAL SIGN;

EID: 67649359898     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802644209     Document Type: Article

References (40)

1. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:335-347 (Pubitemid 46148776)
2. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-359 (Pubitemid 46148777)
3. Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34:909-917 (Pubitemid 34229758)
4. San Juan R, Aguado JM, Lumbreras C, et al. Incidence, clinical characteristics and risk factors of late infection in solid organ transplant recipients: data from the RESITRA Study Group. Am J Transplant 2007;7:964-971 (Pubitemid 46481186)
5. Hope WW, Walsh TJ, Denning DW. Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis 2005;5:609-622 (Pubitemid 41383906)
6. von Eiff M, Roos N, Schulten R, et al. Pulmonary aspergillosis: early diagnosis improves survival. Respiration 1995;62:341-347
7. Prentice HG, Kibbler CC, Prentice AG. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol 2000;110:273-284 (Pubitemid 30646851)
8. Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006;50:2009-2015
9. Groll AH, Walsh TJ. Posaconazole: clinical pharmacology and potential for management of fungal infections. Expert Review of Anti-infective Therapy 2005;3:467-487 (Pubitemid 41223214)
10. Raad II, Hachem RY, Herbrecht R, et al. Posaconazole as salvage treatment of invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006;42:1398-1403
11. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007;44:2-12 (Pubitemid 44968977)
12. Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006;50:658-666 (Pubitemid 43190980)
13. van Burik J-AH, Hare RS, Solomon HF, et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006;42:e61-5
14. Noxafil 40 mg/ml oral suspension [Summary of Product Characteristics] [prescribing information]. Brussels, Belgium: SP Europe; March 2008
15. NOXAFIL® (posaconazole) oral suspension [prescribing information]. Kenilworth, NJ: Schering Corporation; May 2008
16. Courtney R, Radwanski E, Lim J, et al. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother 2004;48:804-808 (Pubitemid 38280328)
17. Ezzet F, Wexler D, Courtney R, et al. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 2005;44:211-220 (Pubitemid 40188942)
18. Courtney R, Wexler D, Radwanski E, et al. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2003;57:218-222
19. Courtney R, Pai S, Laughlin M, et al. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003;47:2788-2795 (Pubitemid 37040249)
20. Krishna G, Sansone-Parsons A. Pharmacokinetics of posaconazole in healthy volunteers: a meta-analysis of five phase 1 studies. Presented at: 41st American Society of Health-System Pharmacists Midyear Clinical Meeting and Exhibition, Anaheim CA, December 3-7, 2006
21. Wexler D, Courtney R, Richards W, et al. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004;21:645-653 (Pubitemid 38447146)
22. Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006;26:1730-1744 (Pubitemid 44885328)
23. Wang EJ, Lew K, Casciano CN, et al. Interaction of common azole antifungals with P glycoprotein. Antimicrob Agents Chemother 2002;46:160-165 (Pubitemid 34031618)
24. Sattler M, Guengerich FP, Yun C-H, et al. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992;20:753-761
25. Combalbert J, Fabre I, Fabre G, et al. Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metab Dispos 1989;17:197-207
26. Krieter P, Flannery B, Musick T, et al. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004;48:3543-3551 (Pubitemid 39129357)
27. Shen JX, Krishna G, Hayes RN. A sensitive liquid chromatography and mass spectrometry method for the determination of posaconazole in human plasma. J Pharm Biomed Anal 2007;43:228-236 (Pubitemid 44856187)
28. Cervelli MJ. Fluconazole-sirolimus drug interaction [letter]. Transplantation 2002;74:1477-1478
29. Said A, Garnick JJ, Dieterle N, et al. Sirolimus-itraconazole interaction in a hematopoietic stem cell transplant recipient. Pharmacotherapy 2006;26:289-295 (Pubitemid 43201879)
30. Kuypers DR, Claes K, Evenepoel P, et al. Drug interaction between itraconazole and sirolimus in a primary renal allograft recipient [letter]. Transplantation 2005;79:737 (Pubitemid 40463185)
31. Mathis AS, Shah NK, Friedman GS. Combined use of sirolimus and voriconazole in renal transplantation: a report of two cases. Transplant Proc 2004;36:2708-2709 (Pubitemid 40036818)
32. Marty FM, Lowry CM, Cutler CS, et al. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006;12:552-559 (Pubitemid 43956360)
33. Thomas PP, Manivannan J, John GT, et al. Sirolimus and ketoconazole co-prescription in renal transplant recipients. Transplantation 2004;77:474-475 (Pubitemid 38209757)
34. VFEND® (voriconazole) [prescribing information]. New York, NY: Pfizer Inc., November 2006
35. Sansone-Parsons A, Krishna G, Martinho M, et al. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 2007;27:825-834 (Pubitemid 46849426)
36. Koselj M, Bren A, Kandus A, et al. Drug interactions between cyclosporine and rifampicin, erythromycin, and azoles in kidney recipients with opportunistic infections. Transplant Proc 1994;26:2823-2824 (Pubitemid 24329329)
37. Foradori A, Mezzano S, Videla C, et al. Modification of the pharmacokinetics of cyclosporine A and metabolites by the concomitant use of Neoral and diltiazem or ketoconazol in stable adult kidney transplants. Transplant Proc 1998;30:1685-1687 (Pubitemid 28399280)
38. Florea NR, Capitano B, Nightingale CH, et al. Beneficial pharmacokinetic interaction between cyclosporine and itraconazole in renal transplant recipients. Transplant Proc 2003;35:2873-2877 (Pubitemid 38102077)
39. Rapamune® (sirolimus) oral solution and tablets [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc., January 2006
40. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000;38:41-57 (Pubitemid 30055093)